A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Alliance Foundation Trials, LLC
Start Date
July 25, 2017
End Date
May 31, 2018
Administered By
Duke Cancer Institute
Awarded By
Alliance Foundation Trials, LLC
Start Date
July 25, 2017
End Date
May 31, 2018